• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

The majority of FDA-approved drug trials recruit from low- and middle-income countries

byDavid XiangandKiera Liblik
December 9, 2022
in Cardiology, Chronic Disease, Neurology, Oncology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This study found that a high proportion of Food and Drug Administration (FDA) drug trials recruit participants from low- and middle-income countries (LMICs).

2. Cardiovascular trials had the highest proportion of participants recruited from LMICs. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nearly one-third of phase three trials sponsored by large pharmaceutical companies recruit participants from outside of the United States. Many drugs used in North America are also tested abroad, including (LMICs). While recruiting from LMICs can increase population diversity, expedite recruitment, and lower research costs, there are also ethical issues with recruiting from LMICs. These include exposure to unproven treatments and exploitation of these participants. However, there is a gap in knowledge as to understanding the extent to which pivotal trials, defined as trials that support a determination of efficacy, recruit from LMICs, and the proportion of participants from each country need to be better characterized and consistently reported. Overall, this study found that most pivotal trials for cancer, cardiovascular disease, and neurology recruited participants from LMICs. This study was limited by only studying FDA-approved drugs related to cancer, cardiovascular, or neurologic conditions and included only a sample of cancer drugs. Nevertheless, these study’s findings are significant, demonstrating that most pivotal trials for FDA-approved drugs recruit participants from LMICs.

Click to read the study in AIM

Relevant Reading: Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs

RELATED REPORTS

Time-restricted eating does not confer changes in sleep, mood, or quality of life

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation

In-Depth [cross-sectional analysis]: This cross-sectional analysis utilized the FDA database “Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals” to identify all drugs and biologics initially approved from 2012 to 2019 for cancer, cardiovascular diseases, and neurologic conditions. Participant information was extracted from the publication reporting primary efficacy results (such a publication was found for every trial in the sample), medical and statistical reviews from FDA approval records, and ClinicalTrials.gov. The primary outcome measured was the proportion of pivotal trials enrolling participants in LMICs. Outcomes in the primary analysis were assessed by determining the proportion of trials recruited from at least one LMIC during their enrollment period. Based on the primary analysis, 56% in cancer, 79% in cardiovascular disease, and 56% in neurology recruited from an LMIC. For multi-country trials, country-level enrollment figures were unavailable for 71 trials (55%). For those reporting per country enrollment, the percentage of participants recruited from LMICs was 8% for cancer trials, 36% for cardiovascular trials, and 17% for neurology trials. Overall, shit study demonstrates that many pivotal trials for FDA-approved drugs recruit participants from LMICs, though more public reporting of country-level information on recruitment is needed.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancerCancer drugscardiologyCardiology drugscardiovascular diseaseDrug approvalFDA approvalFood and Drug Administration (FDA)LMICslow-income and middle-income countriesneurological diseaseneurologyNeurology drugsoncologypublic health
Previous Post

Maternal unintentional injury during pregnancy associated with higher risk of cerebral palsy

Next Post

Bepirovirsen may reduce disease burden in patients with chronic hepatitis B

RelatedReports

Provision of medically-tailored meals linked with lower admissions and medical spending
Chronic Disease

Time-restricted eating does not confer changes in sleep, mood, or quality of life

July 4, 2025
All Specialties

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

July 4, 2025
#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
All Specialties

#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation

July 3, 2025
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

July 2, 2025
Next Post
Spleen elastography may be effective in the diagnosis of portal hypertension

Bepirovirsen may reduce disease burden in patients with chronic hepatitis B

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Artificial rupture of membranes alone is effective for induction in women with previous C-section

Bystander and first-responder initiated CPR associated with improved outcomes

Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest – the SAMBA trial

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.